Barney S Graham

USPTO Granted Patents = 43 (Patent Applications = 22)

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 5 (Patent Applications = 14)

Average Co-Inventor Count = 6.6

ph-index = 6

Forward Citations = 127(Granted Patents)

Location History:

Nashville, TN (US) (2000 - 2004)
Rockville, MD (US) (2006 - 2024)
Bethesda, MD (US) (2018 - 2024)
Smyrna, GA (US) (2023 - 2024)

Company Filing History:

41 out of 3,539

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Vanderbilt University

patents

4. 2 out of 1,187

The Scripps Research Institute

patents

5. 2 out of 2

Abcellera Biologies Inc.

Institute for Research in Biomedicine

patents

8. 2 out of 8,684

US Government As Represented by the Secretary of the Army

Xiamen Innovax Biotech Co., Ltd.

Korea Center for Disease Control and Prevention

patents

14. 1 out of 1

Abcellera Biologics Inc.

patent

15. 1 out of 531

Glaxosmithkline Biologicals Sa

University of Washington

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

Areas of Expertise:

Nanoparticle-Based Vaccines

Influenza Virus Vaccines

Prefusion RSV F Proteins

Stabilized Hemagglutinin Trimers

Anti-Coronavirus Antibodies

Zika Viral Antigen Constructs

Nipah Virus Immunogens

Immunoglobulin Single Variable Domain Antibody

Middle East Respiratory Syndrome Immunogens

Self-Assembling Insect Ferritin Nanoparticles

Neutralizing Antibodies to Ebola Virus

Chimeric Virus Proteins

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12433943 - Nanoparticle-based influenza virus vaccines and uses thereof (2025-10-07),

2. 12275758 - Prefusion RSV F proteins and their use (2025-04-14),

3. 12268737 - Stabilized influenza hemagglutinin stem region trimers and uses thereof (2025-04-08),

4. 12172038 - Anti-coronavirus antibodies and methods of use (2024-12-24),

5. 12077572 - Monoclonal antibody for spike protein of middle east respiratory syndrome coronavirus, and use thereof (2024-09-03),

6. 12018051 - Recombinant human parainfluenza virus type 1 expressing a chimeric RSV/HPIV1 f protein and uses thereof (2024-06-25),

7. 11981707 - Prefusion RSV F proteins and their use (2024-05-14),

8. 11969466 - Stabilized influenza hemagglutinin stem region trimers and uses thereof (2024-04-30),

9. 11964010 - Prefusion coronavirus spike proteins and their use (2024-04-23),

10. 11939356 - Self-assembling insect ferritin nanoparticles (2024-03-26),

11. 11938221 - Multivalent nanoparticle-based vaccines (2024-03-26),

12. 11890339 - Nipah virus immunogens and their use (2024-02-06),

13. 11878998 - Prefusion RSV F proteins and their use (2024-01-23),

14. 11793871 - Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof (2023-10-24),

15. 11780885 - Zika viral antigen constructs (2023-10-10),

Title: The Pioneering Inventor: Barney S. Graham

Introduction:

Barney S. Graham, a visionary inventor based in Rockville, MD (US), has made significant contributions to the field of biotechnology and public health. With a total of 28 patents to his name, Graham's innovative spirit and dedication to scientific excellence have propelled him to the forefront of vaccine development and research.

Latest Patents:

Graham's recent patents include groundbreaking work on "Multivalent nanoparticle-based vaccines" and "Prefusion RSV F proteins and their use." These innovations focus on developing novel nanoparticle-based vaccines that induce a broad immune response to various infectious agents, such as influenza viruses and Respiratory Syncytial Virus (RSV).

Career Highlights:

Throughout his illustrious career, Graham has worked with prestigious institutions such as the United States of America, represented by the Department of Health and Human Services, and Vanderbilt University. His pioneering research has not only advanced the field of biotechnology but has also paved the way for transformative solutions to global health challenges.

Collaborations:

Graham has collaborated with esteemed experts in the field, including Masaru Kanekiyo and Peter D. Kwong. These collaborations have led to the development of innovative vaccines and therapeutics that have the potential to revolutionize the prevention and treatment of infectious diseases.

Conclusion:

In conclusion, Barney S. Graham's impact as an inventor and researcher is truly remarkable. His patented inventions in the realm of vaccine development reflect his unwavering commitment to advancing public health and tackling pressing global challenges. Graham's legacy as a pioneering inventor continues to inspire future generations of researchers and inventors to push the boundaries of scientific innovation.

This text is generated by artificial intelligence and may not be accurate.